查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1136899

2022-2029 年全球急性冠狀動脈綜合徵市場

Global Acute Coronary Syndrome Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

全球急性冠狀動脈綜合徵市場的增長受到多種因素的推動，包括急性冠狀動脈綜合徵患者的激增、慢性病患病率的上升以及高血壓、高血壓和肥胖病例的上升。 .

全球慢性病患病率上升和技術進步不斷推動市場增長。

由於全球不健康的生活方式和環境變化，心力衰竭、心血管疾病和冠狀動脈疾病等慢性疾病的患病率不斷上升，這正在推動市場發展。根據國家健康和營養檢查調查 (NHANES) 數據 (2020)，估計有 620 萬美國 20 歲及以上成年人 (2.2%) 患有心力衰竭。超過 570 萬美國人患有心力衰竭，每年診斷出大約 915,000 例新病例。對於晚期心力衰竭患者，心室輔助裝置將血液泵入全身以支持虛弱的心臟。

根據美國心臟協會 2022 年報告，在社會經濟條件較差的診所接受治療的冠狀動脈疾病（服務費）的醫療保險患者因不穩定型心絞痛住院的風險增加。事實證明。因此，這些冠狀動脈疾病正在增加，導致急性冠狀動脈市場的增長。

治療急性冠狀動脈綜合徵的技術進步也在推動全球心臟輔助設備的增長。例如，2021 年 6 月，雅培宣布它可以支持對機械循環支持設備不斷增長的需求，以充分治療晚期心力衰竭。

與治療急性冠狀動脈綜合徵相關的高成本將阻礙市場增長。

然而，在亞洲等價格敏感地區，急性冠狀動脈綜合徵藥物的高成本可能會影響市場。在這些地區，患者和醫生更喜歡更便宜的治療和手術。急性冠狀動脈綜合徵的藥物價格昂貴。這是急性冠狀動脈綜合徵市場增長面臨的主要全球挑戰之一。

COVID-19 影響分析

大流行還導致供應鏈中斷，影響全球醫療產品市場。大流行正在對全球金融預期、供應鏈、運營、危機應對策略等產生負面影響。由於 COVID-19 的傳播導致關閉和旅行限制，新興急性冠狀動脈綜合徵藥物的製造商面臨挑戰。由於 COVID-19 感染的傳播對主要經濟體產生了重大影響，急性冠狀動脈綜合徵藥物的生產受到了很大影響。

市場參與者正在改變他們的長期和短期增長戰略，利用研究市場和創造尖端產品來抗擊這一流行病。即使 COVID-19 損害了急性冠狀動脈綜合徵行業，重要的是要盡快為業務運營製定備用計劃。

您將可以訪問全球急性冠狀動脈綜合徵市場報告中大約 40 多個市場數據表、45 多個數字和 200 頁（大約）。

內容

第一章市場研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 慢性病增加
      • 老年人口增加
    • 約束因素
      • 根治性手術費用高
      • 與心血管設備相關的高價
      • 嚴格監管
    • 商機
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按類型

  • ST段抬高型心肌梗死
  • 非 ST 段抬高型心肌梗死
  • 不穩定型心絞痛

第8章藥物

  • 抗血栓藥物
  • 降壓藥
  • 他汀類藥物

第 9 章，最終用戶

  • 醫院
  • 專科診所
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準

第 12 章公司簡介

  • Teva Pharmaceuticals
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Dr. Reddy's Laboratories
  • Boehringer Ingelheim
  • Johnson & Johnson
  • Merck
  • Novartis
  • Amgen Inc.
  • AbbVie Inc.
  • AstraZeneca PLC
  • GlaxoSmithKline Plc

第 13 章全球急性冠狀動脈綜合徵市場-DataM

簡介目錄
Product Code: DMPH875

Market Overview

Acute Coronary Syndrome Market was valued at US$ 28,992.31 million in 2021 and is estimated to reach US$ 78,626.54 million by 2029, growing at a CAGR of 8.74% during the forecast period (2022-2029).

Acute coronary syndrome (ASC) occurs when a blood clot suddenly forms within a coronary artery, usually due to the acute rupture of an atherosclerotic plaque. The blood clot may produce partial or complete blockage of the artery, placing the heart muscle supplied by that artery in immediate jeopardy.

Market Dynamics

The global acute coronary syndrome market growth is driven by many factors, such as the rapid surge in acute coronary syndrome cases, the rising prevalence of chronic diseases and increasing cases of high blood pressure, hypertension and obesity.

The increasing prevalence of the chronic disease across the globe and rising technological advancements are driving the market growth.

The market is driven by the rising prevalence of chronic ailments like heart failure, cardiovascular disease, and coronary artery disease due to unhealthy lifestyles and changing environments worldwide. According to the National Health and Nutrition Examination Survey (NHANES) data (2020), an estimated 6.2 million American adults ≥20 years of age (2.2%) had heart failure. More than 5.7 million Americans suffer from heart failure, and approximately 915,000 new patients are diagnosed annually. For patients with advanced heart failure, ventricular assist devices support the weakened heart by pumping blood through the body.

According to the American Heart Association report 2022, Medicare patients (service fee) with coronary artery disease who received treatment at socioeconomically impoverished practices were at higher risk of being admitted for unstable angina. Hence these coronary artery diseases are increasing, leading to the growth of the acute coronary market.

Increasing technological advancements in acute coronary syndrome treatment are also fuelling the growth of cardiac assist devices globally. For instance, in Jun 2021, Abbott announced that the company could support the growing demand for mechanical circulatory support devices to treat advanced heart failure properly.

The high cost associated with acute coronary syndrome treatment will hamper the market's growth.

However, in price-sensitive regions such as Asia, the high cost of acute coronary syndrome therapeutics may impact the market. In these areas, patients and doctors prefer less expensive therapies or surgeries. Acute coronary syndrome treatments are expensive. This is one of the major global challenges to the acute coronary syndrome market's growth.

COVID-19 Impact Analysis

The pandemic has also caused supply chain disruptions, impacting the world market for medical products. The pandemic has negatively impacted global financial expectations, supply chains, operations, and crisis response strategies. Due to lockdowns and travel restrictions brought on by the spread of COVID-19, makers of novel acute coronary syndromes treatment experienced problems. Because the spread of COVID-19 infections badly impacted major economies, acute coronary syndrome therapeutics production was greatly impacted.

Market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Even though COVID-19 harms the acute coronary syndrome industry, preparing and implementing backup plans as soon as possible for business operations is crucial.

Segment Analysis

The ST-elevation myocardial infarction segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

ST-elevation myocardial infarction shows significant growth, accounting for the largest market share, due to the regulatory approval for ST-elevation myocardial infarction drugs. For instance, in Jun 2020, AstraZeneca announced that Brilinta (ticagrelor) received approval from US Food and Drug Administration. Brilinta is used for reducing first stroke or heart attack risk in patients at high risk with coronary artery disease.

New technological advancements, novel pipelines, and clinical research in acute coronary syndrome treatments will also lead to market growth. For instance, in Aug 2022, AstraZeneca presented its novel results from the analysis of phase III trials of DAPA-HF and DELIVER that shows the mortality benefit of Farxiga over placebo in heart failure patients.

Geographical Analysis

The North American region holds the largest global acute coronary syndrome market.

North America dominates the acute coronary syndrome market and is expected to show a similar trend over the forecast period. The growth of North American acute coronary syndrome can be attributed to the rising prevalence of heart failure cases and the surge in the geriatric population. Strong healthcare infrastructure and an increase in research and development expenditure are to blame for this supremacy.

Furthermore, the rising prevalence of chronic diseases like myocardial infarction, unstable angina, etc., in this region due to unhealthy lifestyles and diets has propelled acute coronary syndrome treatment demand in the market. According to the American Heart Association report 2020, approximately 790,000 people in the U.S. have heart attacks yearly. The rising number of people suffering from cardiovascular diseases and growing technological advancements and mergers or acquisitions by key players boost the demand for acute coronary syndrome treatment in this region. For instance, in Jun 2021, Abiomed announced its acquisition of a precardiac catheter developer that provides less invasive options for treating patients with acute decompensated heart failure.

Competitive Landscape

The acute coronary syndrome market is highly competitive with local and global companies. Some key players contributing to the market's growth are Teva Pharmaceuticals, Dr. Reddy's Laboratories, Boehringer Ingelheim, Johnson & Johnson, Merck, Novartis, Amgen Inc., AbbVie Inc., AstraZeneca PLC and GlaxoSmithKline Plc among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the acute coronary syndrome market globally. For instance, in May 2022, Johnson and Johnson announced that its results from XARELTO (rivaroxaban), combined with the acetylsalicylic acid (XATOA) registry, were published in the European Heart Journal of the European Society of Cardiology. This study supports XARELTO's dual pathway inhibition role in coronary artery disease patients.

In Sep 2022, Abiomed announced that U.S. FDA approved two clinical research Impella heart pumps that can be used in acute myocardial infarction.

Teva Pharmaceuticals.

Overview:

Teva Pharmaceuticals is a multinational pharmaceutical company established in 1901 and headquartered in Tel Aviv, Israel. It specializes in generic drugs (primary), active pharmaceutical ingredients and proprietary pharmaceuticals.

Product Portfolio:

Ranexa: Ranolazine is a medicine used to treat chest pain related to the heart, such as chronic stable angina. It improves the blood flow toward the heart and makes it work efficiently. It can be used in combination with other medicines.

The global acute coronary syndrome market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of chronic diseases
      • 4.1.1.2. Growing geriatric population
    • 4.1.2. Restraints:
      • 4.1.2.1. The high cost of therapeutic surgeries
      • 4.1.2.2. High price associated with the cardiovascular devices
      • 4.1.2.3. Stringent regulations
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. ST-Elevation Myocardial Infarction*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Non-ST-Elevation Myocardial Infarction
  • 7.4. Unstable Angina

8. By Drugs

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 8.1.2. Market Attractiveness Index, By Drugs
  • 8.2. Antithrombotic*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Antihypertensive
  • 8.4. Statin Drugs

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospital*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Specialty Clinics
  • 9.4. Other

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Teva Pharmaceuticals*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Dr. Reddy's Laboratories
  • 12.3. Boehringer Ingelheim
  • 12.4. Johnson & Johnson
  • 12.5. Merck
  • 12.6. Novartis
  • 12.7. Amgen Inc.
  • 12.8. AbbVie Inc.
  • 12.9. AstraZeneca PLC
  • 12.10. GlaxoSmithKline Plc

LIST NOT EXHAUSTIVE

13. Global Acute Coronary Syndrome Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us